Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid

Conclusions
EPA-FFA therapy is safe and well tolerated in patients with advanced CRC undergoing liver surgery. EPA-FFA may have antiangiogenic properties. Remarkably, limited preoperative treatment may provide postoperative OS benefit. Phase III clinical evaluation of prolonged EPA-FFA treatment in CRCLM patients is warranted.

Trial Identifier:
ClinicalTrials.gov NCT01070355.

Source: Gut - October 2, 2014 Category: Gastroenterology Authors: Cockbain, A. J., Volpato, M., Race, A. D., Munarini, A., Fazio, C., Belluzzi, A., Loadman, P. M., Toogood, G. J., Hull, M. A. Tags: Colon cancer, Hepatic cancer Source Type: research